Reviva Pharmaceuticals Holdings, Inc. Retained Earnings
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Retained Earnings of -$189.78 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$189.78M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$187.33M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$184.14M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$180.77M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$189.78M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$187.33M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$184.14M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$180.77M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$176.76M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$170.71M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$164.27M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$158.01M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$149.65M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$141.79M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$134.35M 10-K · filed 2025-04-03 | |
| 2023-09-30 | -$125.00M 10-K · filed 2024-04-15 | -$120.71M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$113.65M 10-K · filed 2024-04-15 | -$110.22M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$101.95M 10-K · filed 2024-04-15 | -$97.77M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$95.09M 10-K · filed 2024-04-15 | -$91.17M 10-K · filed 2023-03-30 |
| 2022-09-30 | -$85.86M 10-K · filed 2024-04-15 | -$83.05M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$79.54M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$74.20M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$66.83M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$63.15M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$60.87M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$59.26M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$58.31M 10-K · filed 2022-03-15 | |
| 2020-11-30 | $172.03K 10-Q · filed 2021-01-14 | |
| 2020-08-31 | $520.24K 10-Q · filed 2020-10-14 | |
| 2020-05-31 | $1.04M 10-Q · filed 2020-07-07 | |
| 2020-02-29 | $1.19M 10-Q · filed 2021-01-14 | |
| 2019-12-31 | -$54.53M 10-K/A · filed 2021-05-07 | |
| 2019-11-30 | $1.32M 10-Q · filed 2020-01-10 | |
| 2019-08-31 | $1.19M 10-Q · filed 2019-10-08 | |
| 2019-05-31 | $912.56K 10-Q · filed 2019-07-03 | |
| 2019-02-28 | $574.13K 10-K · filed 2020-05-04 | |
| 2018-11-30 | $267.57K 10-Q · filed 2019-01-09 | |
| 2018-08-31 | $4.35K 10-Q · filed 2018-10-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |